๐๐ป As #ESMO2024 comes to a close, we want to thank everyone who visited our booth and engaged with us. After some incredible days of insights, discussions, and connections, we're leaving the congress more committed than ever to advance #oncology care through innovative medical imaging solutions. A special thanks to our dedicated teamโรngel Alberich-Bayarri, Fuensanta Bellvรญs Bataller, Claire Palacin, Ana Jimenez Pastor, Adriana Arpa, Javier Pizcueta Pastor, Alejandra Estepa Fernรกndez, PhD, David Bazaga, Anna Noguรฉ Infante, and Marta Martinez Calle, Ph.D.โfor representing Quibim with passion and expertise. Until next time, let's continue to push the boundaries of what's possible in oncology. #CancerCare #Oncology #Innovation #Quibim #Healthcare
At the recent Asociaciรณn Espaรฑola contra el Cรกncer roundtable, our Director of Grants and Innovation Ana Blanco Sanchez, PhD, PMPยฎ discussed with leading experts how new technologies are transforming #cancercare. Special thanks to the other participants for their interesting contributions: หLeonor Cerdรก Alberich, Josรฉ Pรฉrez Calatayud, Marรญa Cruz Torres Gรณrriz, and Marisa Villafranca Iturre. #CancerResearch #AIinHealth #MedicalInnovation #PatientCare
๐๐ป Hola, Barcelona! The #QuibimTeam is here at #ESMO2024, ready to engage with all of you who are part of the global oncology and healthcare community. Visit us at Booth #526 to meet our team or book a demo to discover our latest medical imaging solutions here: https://lnkd.in/dhMgFu_2 #OncologyCare #CancerCare #PrecisionMedicine
An NHS review report has been published today with the aim of identifying points for improvement. The report is the result of a nine-week review conducted by independent expert and NHS surgeon Lord Darzi. With the findings in mind, our CEO and Co-Founder รngel Alberich-Bayarri makes the following statement: โ๐๐ถ๐ช๐ฃ๐ช๐ฎ ๐ธ๐ฆ๐ญ๐ค๐ฐ๐ฎ๐ฆ๐ด ๐๐ฐ๐ณ๐ฅ ๐๐ข๐ณ๐ป๐ช ๐ฐ๐ง ๐๐ฆ๐ฏ๐ฉ๐ข๐ฎ'๐ด ๐ณ๐ฆ๐ฑ๐ฐ๐ณ๐ต ๐ข๐ฏ๐ฅ ๐ฌ๐ฆ๐บ ๐ง๐ช๐ฏ๐ฅ๐ช๐ฏ๐จ ๐ต๐ฉ๐ข๐ต ๐ต๐ฉ๐ฆ ๐๐๐ ๐ฏ๐ฆ๐ฆ๐ฅ๐ด ๐ต๐ฐ ๐ฆ๐ฎ๐ฃ๐ณ๐ข๐ค๐ฆ ๐ต๐ฆ๐ค๐ฉ๐ฏ๐ฐ๐ญ๐ฐ๐จ๐ช๐ค๐ข๐ญ ๐ช๐ฏ๐ฏ๐ฐ๐ท๐ข๐ต๐ช๐ฐ๐ฏ, ๐ฆ๐ด๐ฑ๐ฆ๐ค๐ช๐ข๐ญ๐ญ๐บ ๐ต๐ฉ๐ฆ ๐ถ๐ด๐ฆ ๐ฐ๐ง ๐ฃ๐ช๐จ ๐ฅ๐ข๐ต๐ข ๐ด๐ฆ๐ต๐ด ๐ข๐ฏ๐ฅ #๐๐ ๐ต๐ฐ ๐ต๐ณ๐ข๐ฏ๐ด๐ง๐ฐ๐ณ๐ฎ ๐ฑ๐ข๐ต๐ช๐ฆ๐ฏ๐ต ๐ฐ๐ถ๐ต๐ค๐ฐ๐ฎ๐ฆ๐ด. ๐๐, ๐ช๐ฏ๐ค๐ญ๐ถ๐ฅ๐ช๐ฏ๐จ ๐ช๐ต๐ด ๐ข๐ฑ๐ฑ๐ญ๐ช๐ค๐ข๐ต๐ช๐ฐ๐ฏ ๐ต๐ฐ ๐ฎ๐ฆ๐ฅ๐ช๐ค๐ข๐ญ ๐ช๐ฎ๐ข๐จ๐ช๐ฏ๐จ, ๐ค๐ข๐ฏ ๐ข๐ฏ๐ฅ ๐ด๐ฉ๐ฐ๐ถ๐ญ๐ฅ ๐ฑ๐ญ๐ข๐บ ๐ข ๐ค๐ฆ๐ฏ๐ต๐ณ๐ข๐ญ ๐ณ๐ฐ๐ญ๐ฆ ๐ช๐ฏ ๐ต๐ฉ๐ฆ ๐ฅ๐ฆ๐ต๐ฆ๐ค๐ต๐ช๐ฐ๐ฏ ๐ข๐ฏ๐ฅ ๐ฅ๐ช๐ข๐จ๐ฏ๐ฐ๐ด๐ช๐ด ๐ฐ๐ง ๐ค๐ข๐ฏ๐ค๐ฆ๐ณ ๐ข๐ฏ๐ฅ ๐ฐ๐ต๐ฉ๐ฆ๐ณ ๐ฅ๐ช๐ด๐ฆ๐ข๐ด๐ฆ๐ด, ๐ข๐ด ๐ธ๐ฆ๐ญ๐ญ ๐ข๐ด ๐ช๐ฏ ๐ฅ๐ณ๐ถ๐จ ๐ฅ๐ฆ๐ท๐ฆ๐ญ๐ฐ๐ฑ๐ฎ๐ฆ๐ฏ๐ต ๐ข๐ฏ๐ฅ ๐ค๐ณ๐ช๐ต๐ช๐ค๐ข๐ญ ๐ค๐ข๐ณ๐ฆ ๐ฅ๐ฆ๐ญ๐ช๐ท๐ฆ๐ณ๐บ, ๐ช๐ฎ๐ฑ๐ณ๐ฐ๐ท๐ช๐ฏ๐จ ๐ฑ๐ข๐ต๐ช๐ฆ๐ฏ๐ต ๐ฐ๐ถ๐ต๐ค๐ฐ๐ฎ๐ฆ๐ด.โ https://lnkd.in/db-Cbc_B
๐ A must-read before hashtag#ESMO2024: As we approach one of the major oncology events of the year, we wanted to reflect on the evolving #OncologyCare landscape with this interview with Oscar Juan, MD, Phd, thoracic medical oncologist. Whether you are a clinician, researcher or healthcare professional, this post offers valuable insights as you look ahead to the congress โฌ๏ธ https://lnkd.in/dkaBGnxe #PrecisionMedicine #HealthInnovation
๐ Last week we asked you about the potential of radiomics in #healthcare. Many of you recognize the value of radiomics in improving #PatientCare and increasing efficiency in drug development, consistent with the latest trends observed in the industry. ๐ฏ Radiomics is taking center stage in Precision Medicine. With 40 #ASCO2024 abstracts discussing its applications, it is clear that this technology is having a significant impact. Scroll through the carousel to learn more about this topic โฌ #Radiomics #PrecisionMedicine #HealthInnovation
During #ProstateHealthAwarenessMonth, it is important to highlight that while prostate screening is crucial to saving lives, it continues to present numerous needs. The effectiveness of prostate cancer imaging depends on sensitivity, which is essential for accurate diagnosis, effective treatment planning, and improved patient outcomes. The QP-Prostateยฎ imaging tool, the only one trained with both systematic and targeted biopsies increases sensitivity from 79.8% up to 90.4%, and significantly enhances the detection of #ProstateCancer, with the goal of reducing mortality and improving patients' quality of life. #ProstateCancer #ProstateHealth #MensHealth
The path to bringing a new drug to market is challenging: costly trials, lengthy timelines, and the risk of failure due to poor patient selection and limited biomarker #data. ๐๐ผ๐ ๐ฐ๐ฎ๐ป ๐ค๐ฃ-๐๐ป๐๐ถ๐ด๐ต๐๐ ๐ต๐ฒ๐น๐ฝ? โก Smarter Patient Selection โก Non-Invasive Monitoring โก Comprehensive Biomarkers โก Efficient Trials Ready to enhance your drug development process? Download our infographic dashboards for a deeper look: https://lnkd.in/dbCRz9SK #DrugDevelopment #AIinHealthcare #MedicalImaging #ESMO2024
Clinicians are sometimes faced with some limitations that lead to misdiagnosis and patient uncertainty. QP-Prostateยฎ - the only tool trained with both systematic and targeted biopsies - addresses this problem by increasing sensitivity from 79.8% up to 90.4%. See how QP-Prostateยฎ can improve your practice: book a demo with our team today! https://lnkd.in/d67y-mqn #ProstateCancer #ProstateHealth #MensHealth #ProstateHealthAwarenessMonth
As the healthcare landscape rapidly evolves, we're eager to hear your thoughts on radiomics, a pioneering field within #PrecisionMedicine. How knowledgeable and interested do you think healthcare professionals are in radiomics? Join the conversation, and let's explore the perspectives in our field on this transformative technology! #Radiomics #AIInHealth #InnovationInHealth #Quibim
